cyrilzakka/clinical-trials huggingface dataset:
Pilot Study of a 14-day Modified Sequential Therapy for Helicobacter Pylori Infection

The purpose of this study is to assess efficacy of a 14-day sequential therapy for the rescue treatment of refractory Helicobacter pylori infection, and whether it is safe while maintaining an ideal eradication rates.

Half of the world's population is infected with Helicobacter pylori. Strong evidence supports that H.pylori eradication is an effective approach to reduce the risk of developing gastric cancer. However, eradication rates of first-line therapy decreased over years due to the rapidly emerging antibiotic resistance of H. pylori worldwide. An ideal rescue therapeutic regimen to cure refractory H.pylori infection is currently warranted.

Traditional sequential therapy failed to achieve an ideal eradication rates (over\>95%) as a third line treatment in the region with high antibiotic resistance. The investigator's study aims to evaluate the efficacy 14-day modified sequential therapy in the patients with two or more treatment failure, and whether the adverse effects of this new modified sequential therapy are tolerable.

Eligibility Criteria:
Inclusion Criteria:

* Patients aged 18-70 with persistent H. pylori infection.
* Patients failed at least three different standard eradication therapies before. Previous standard eradication therapy was defined as a 10-day or 14-day quadruple regimen designed according to Maastricht V report.

Exclusion Criteria:

* Patients unable or unwilling to receive gastroscopy.
* Patients treated with H2-receptor antagonist, PPI, bismuth and antibiotics in the previous 4 weeks.
* Patients with gastorectomy, acute GI bleeding and advanced gastric cancer.
* History of allergy to any of the drugs used in the study.
* Severe concomitant cardiovascular, respiratory, or endocrine diseases, clinically significant renal or hepatic disease, hematologic disorders and any other clinically significant medical condition that could increase risk.
* Currently pregnant or lactating.
* Severe neurologic or psychiatric disorders.
* Alcohol abuse or drug addiction.
* Patients with compliance lower than 90% in any previous treatment are not included.
* Inability to provide informed consent and other situations that could interfere with the examination or therapeutic protocol.
Gender-specific aEEGs and Outcome in Preterms

Background and objectives: Male sex is a risk factor for poor neurodevelopmental outcome following preterm birth. The investigators aimed to investigate gender-related differences in amplitude-integrated electroencephalography (aEEG) and to correlate these findings with neurodevelopmental outcome.

Methods: Preterm infants born \<30 weeks' gestational age between 2000 and 2002 were prospectively included. aEEGs obtained within the first two weeks of life were evaluated and classified according to background activity, sleep-wake cycling (SWC) and seizure activity. Outcome was assessed at three years.


Eligibility Criteria:
Inclusion Criteria:

* born\<30 weeks gestational age
* who had aEEGs in first 2 weeks of life
* who were assessed for outcome at 3 years of age

Exclusion Criteria:

* born\>30 weeks gestational age
* had no aEEGs in first 2 weeks of life
* lost for follow-up at 3 years
A Multi-Center Protocol for Obtaining and Storing Human Samples for Immediate or Future Microbial, Immune, or Host Microbe Scientific Study

The intent of this protocol is to salvage human-related material that is normally destined for destruction, so it can be used in infection-related scientific studies.

This clinical material can be studied in order to better understand the molecular, cellular, or ecological components of the infected or potentially infected tissue or device. These studies may be able to provide important insights into the keys of chronic infections, complex infections, medical biofilms, pathogen ecology, and healing.

Eligibility Criteria:
Inclusion Criteria:

* The Subject must be 18 years of age or older.
* The Subject must be mentally competent as determined by the Investigator.

Exclusion Criteria:

* The Subject may not be currently incarcerated.
* The Subject may not be knowingly pregnant.
* The Subject may not be institutionalized.
* The Subject may not be an employee or student of the investigator or sponsor.
The Essential Tremor (ET) and Parkinson Disease (PD) Tremor Acute Stimulation Study

The current study is designed to test the hypothesis that targeted electrical stimulation will result in upper limb tremor reduction in ET and PD patients.

This study will evaluate the effect of Rainbow Medical's stimulation procedure methodology that will be applied temporarily to patients suffering of tremor.

This will be evaluated by assessment of reduction of tremor using accelerometer measurements, patient tremor evaluation diary, tremor rating scale, and the Unified Parkinson's Disease Rating Scale (UPRDS) part III.In addition,tasks for patient with tremor will be conducted before during and after the treatment. The above measurements will provide data on the stimulation procedure effect as compared to baseline.

Eligibility Criteria:
Inclusion Criteria:

* Able to Sign written informed consent in Hebrew.
* Patient agrees to attend all treatment procedures and follow-up evaluations and is willing and able to comply with all study requirements.
* Patient with a clinical diagnosis of idiopathic PD, or ET for more than 3 years.
* Significant tremor for at least one upper limb causing distress or disability.
* Patient should be stable on anti-Parkinson's disease or anti-tremor medication for at least one month prior to study enrollment.

Exclusion Criteria:

* Previous participation in another study with any investigational drug or device within the past 90 days.
* Any active implant (cardiac or other).
* Current pregnancy or attempting to get pregnant (female patient).
* Patient has any major illness or medical condition that in the opinion of the physician would interfere with participation in the study.
* Patient with other significant neurological or psychiatric disease other than Parkinson Disease or Essential Tremor.
* Patient has any other condition expect for PD and ET that induce tremor.
* Patient is treated with drug that may induce tremor.
* Patient abuses drugs or alcohol.
* Any previous thalamotomy, pallidotomy or patient who has undergone a DBS procedure.
* Any anticipated need for surgery during the study.
* Any malignancy in the past 2 years.
* Patient has confirmation of diagnosis of a terminal illness associated with survival \<12 months.
Validation of an Early Warning Score Based Triage System in the Emergency Department

At Bispebjerg Hospital we have introduced an Early Warning Score based triage system , called Bispebjerg Early Warning Score (BEWS), in order to identify critically ill patient on arrival at the emergency department. The purpose of this study is to validate our triage system.


Eligibility Criteria:
Inclusion Criteria:

* "Red" patient
* Seen in our emergency department between 1. april 2009 and 30. september 2009

Exclusion Criteria:

* None
Patient Satisfaction and Oral Healthy Related Quality of Life of Polyetherketoneketone and Metal Framework.

The patients' satisfaction and oral health related quality of life (OHRQL) of different framework material remains uncertain. Thus, the aim of this clinical cross over study was to compare patient satisfaction and OHRQL OF polyetherketoneketone and metal framework for All-on-four implant supported fixed prosthesis

10 completely edentulous patients around age of 50-60 years will be selected for this study from the Outpatient Clinic, Faculty of Dentistry, Mansoura University.

All selected participants will receive a new complete dentures (CD) fabricated with bilateral balanced occlusion utilizing semi-anatomical acrylic teeth. The patients were instructed to wear the dentures for 3 months to develop adequate neuromuscular control, and then, clinical performance and patient satisfaction will be evaluated.

Each participant will receive 4 implants according to the "All-on-4 concept," and the implants will be immediately loaded with mandibular denture. Three months after osseointegration, patients received a definitive fixed detachable prosthesis either from PEKK or metal with composite teeth in a crossover designs. Two sets of patients will be made (10 patients/set) using random-generated numbers created by a computer program (Excel sheet). The first 10 participants will recieve metal framework first. After 3 months, patient satisfaction and OHRQoL will be measured and metal framework will be replaced by PEKK framework. After another 3 months, measurements will be repeated. The second 10 patients received PEKK first, and after 3 months, measurements will be made. Then, PEKK framework was replaced by Metal framework and measurements were repeated after another 3 months.

Eligibility Criteria:
Inclusion Criteria:

* Sufficient available restorative space (from the proposed occlusal plane to soft tissue • covering residual ridge) of at least 20 mm to accommodate all types of tested prosthesis.
* They had completely edentulous maxilla and mandible at least six months after the last extraction.
* Sufficient residual alveolar ridge quantity and quality (D2-D3)
* Maxillary and mandibular residual alveolar ridges covered by healthy non-inflamed mucosa with even compressibility.
* Normal maxillo-mandibular relationship.

Exclusion Criteria:

All diseases or syndromes are contraindicated with implant surgery such as:

* General contraindications for surgical procedures such as patients with head and neck radio therapy, patients with bleeding disorders, hepatic patients.
* Patients with metabolic disorders that affect Osseo integration such as diabetes mellitus, and osteoporosis.
* Long term immunosuppressive and corticosteroid drug therapy.
* Abnormal detrimental habits, e.g. bruxism and clenching.
* Heavy smokers and alcoholic patients.
* All patients will be informed about the steps involved in this research and they will sign a

written consent form of the ethical committee of faculty of dentistry Mansoura University for approval to take part in this research and come to the follow up visits.
DFI and Aneuploidies

IVF is the most commonly employed form of assisted reproductive technologies (ART) for the 10-15% of couples who face difficulties becoming pregnant. Many individuals elect to have their IVF-derived embryos analyzed using pregenetic implantation testing for aneuploidies (PGT-A). The use of PGT-A is particularly beneficial for patients at higher risk for aneuploidy, such as those of advanced maternal age and those faced with recurrent pregnancy loss or recurrent implantation failure.

Segmental aneuploidies are generated when a small piece of a chromosome is gained or lost during cell division, resulting in subchromosomal copy number (CN) changes. The frequency of segmental aneuploidies during the cleavage stage varies between studies, from as low as 3.9% to 15% and up to 70 % with no reported correlation with maternal age. This can be explained by the fact that, unlike whole chromosome aneuploidies, segmental aneuploidies most often involve paternally inherited chromosomes.


Eligibility Criteria:
Inclusion Criteria:

* IVF cycle completed at clinique ovo
* Maternal age between 18 to 43 years included
* PGT-A done on all embryos
* Recent DFI within 1 year of the IVF cycle

Exclusion Criteria:

* Sperm donation
A Study to Evaluate Efficacy and Safety of Deucravacitinib in Participants With Alopecia Areata

The purpose of this study is to evaluate the efficacy of deucravacitinib versus placebo at Week 24 and safety and tolerability of deucravacitinib versus placebo in adults with alopecia areata.


Eligibility Criteria:
Inclusion Criteria:

* Documented clinical diagnosis of alopecia areata (AA) for at least 6 months.
* Current episode of scalp hair loss (at screening) must meet the following criteria: duration at least 6 months; duration of current hair loss episode of AA affecting ≥ 50% of the scalp not exceeding 8 years; scalp hair loss has been stable (no significant spontaneous regrowth \[\> 10%\] over the last 6 months)
* SALT score ≥ 50 at Screening and Day 1. Participant with complete scalp hair loss (SALT score of 100) with or without body hair involvement can be included.

Exclusion Criteria:

* Participant with diffuse-type AA or other forms of hair loss, including traction alopecia, lichen planopilaris, central centrifugal cicatricial alopecia, frontal fibrosing alopecia, etc.
* Other active skin diseases affecting the scalp that in the opinion of the investigator may interfere with accurate assessment of SALT score.
* Extensive tattooing of the scalp that, in the opinion of the investigator, may interfere with the accurate assessment of SALT score.

Other protocol-defined inclusion/exclusion criteria apply.
Utilization of a 3D Printed Customized Knee Extender and At-Home Rehabilitation Program on Patient Outcomes Following ACL Surgery

The purpose of this study is to explore patient outcomes associated with, the use of a 3D printed knee extender device, in conjunction with an at-home rehabilitation program, for patients who are performing knee rehabilitation after anterior cruciate ligament (ACL) surgery.


Eligibility Criteria:
Inclusion Criteria:

* Diagnosed with a primary ACL rupture. Secondary knee pathology such as, but not limited to bone edema, strains, and meniscal pathology are acceptable as long as the primary injury and indication for surgery is the ACL rupture.
* Able and willing to adhere to the study procedures
* Able to consent for self-, or able to assent for self with parental consent

Exclusion Criteria:

* Pregnancy
* Non-English speaking
Effect of Open Chain Versus Closed Chain Segmental Control Exercises on CSA of Lumbar Multifidus Muscle in Chronic MLBP

To investigate the effect of adding open versus closed chain segmental control exercises to conventional treatment program on pain intensity, lumbar ROM, and CSA of multifidus muscle.

* To investigate the effect of adding open versus closed chain segmental control exercises to conventional treatment program on pain intensity.
* To investigate the effect of adding open versus closed chain segmental control exercises to conventional treatment program on lumber ROM.
* To investigate the effect of adding open versus closed chain segmental control exercises to conventional treatment program on CSA of multifidus muscle.
* To investigate the effect of adding open versus closed chain segmental control exercises to conventional treatment program on lumber function.

Eligibility Criteria:
Inclusion Criteria:

1. Patients with chronic low back pain from both genders their age will be ranged and divided into three groups from 25-55 years.
2. Participants with chronic low back pain lasting for more than 6 Months.
3. A patient who can follow the command.
4. A patient who can do exercise.

Exclusion Criteria:

1. Low back pain patients with a history of severe neurological disease or orthopedic disease.
2. History of Psychological Disorder.
3. Unhealthy Patient.
4. Pregnant women.
5. Patient with a spinal tumor.
6. History of any operation related to spine. Ex. Vertebral fracture or dislocation.
Melatonin and Osteogenic Loading on Osteopenia

This study will be assessing the efficacy of melatonin and/or osteogenic loading on modulating bone health in an osteopenic population.


Eligibility Criteria:
Inclusion criteria: To be included in the study, the participant must be a male or female with osteopenia (T-score between -1.0 and -2.5) who is at least 18 years of age. The participant must be willing to undergo an osteogenic loading protocol once per week and/or take a pill (placebo or melatonin) for one year. The participant must also be willing to come to the study location to receive their monthly capsules and to provide urine, have their blood pressure taken and complete questionnaires on 3 occasions (baseline/month 0, month 3 and month 12). The study participants must also be willing to get a DXA scan at months 0 and 12 at one of the three Weinstein Imaging locations.

Exclusion criteria: Women or men with osteoporosis; women or men with osteopenia due to hyperparathyroidism, multiple myeloma, metastatic bone disease, chronic steroid use including corticosteroids; women or men who are on any bone therapies (i.e. bisphosphonates, selective estrogen receptor modulators (SERMs), hormone therapy, teriparatide, and denosumab); men and women with chronic obstructive pulmonary disease (COPD); women or men who smoke; pregnant women; and men or women with muscular dystrophy, unmedicated hypertension, or unrepaired hernia, restrictions to movement and exercise, and parathyroid dysfunctions.
The Thoracic Peri-Operative Integrative Surgical Care Evaluation Trial - Stage III

Despite enormous advances in thoracic surgery and oncology, two critical issues concern patients undergoing curative-intent surgery for lung, gastric and esophageal cancer: first, a majority (\~60%) of patients experience minor and major adverse events occurring during and in the days following surgery; second, patients worry about the significant risk of cancer recurrence and mortality months to years after surgery. These issues, combined with side effects of chemotherapy and radiation, have detrimental effects on health-related quality of life (HRQoL). On a deeper level, there is the problem of an ongoing failure to integrate and evaluate the best of what complementary medicine has to offer surgical oncology care. Too many clinical trials focus on single agent therapies, rather than broad multi-faceted individualized and integrative care interventions that are used in real world settings.

The Thoracic POISE project has the overarching goal of improving care for thoracic cancer patients by impacting HRQoL, reducing surgical adverse events, prolonging overall survival and pioneering integrative care delivery.


Eligibility Criteria:
Inclusion criteria

• Adults eligible for complete resection of lung, gastric or esophageal cancer

Exclusion criteria

* Small cell, carcinoid, or gastrointestinal stromal (GIST) tumours
* Any wedge resections of lung cancer
* History of cancer with active treatment in the last 3 years (not including superficial bladder cancer or non-melanoma skin cancer)
* Patients currently receiving care guided by an ND or who have previously seen an ND in the last 3 months
* Pregnant or breastfeeding women\*
* Any reason which, in the opinion of the Principal Investigator (or delegate), would prevent the subject from participating in the study
* Use of an investigational drug or participation in an investigational study within 30 days prior to starting the study
STRATA: Safe Testing of Risk for AsymptomaTic MicrohematuriA

To evaluate the clinical utility associated with the integration of Cxbladder into the evaluation of subjects presenting with hematuria for evaluation of urothelial carcinoma (UC) without compromising detection of UC.

Randomised two arm pragmatic clinical study to be conducted at multiple sites in US and Canada. The trial will recruit hematuria subjects, presenting to qualified sites (academic, community), who are being evaluated for urothelial carcinoma (UC). Up to 100 consecutive eligible subjects will be recruited per site.

Eligibility Criteria:
Inclusion Criteria:

* Patient is undergoing investigation of recent confirmed hematuria, as defined by the AUA/SUFU Guideline (Barocas DA, Boorjian SA, Alvarez RD et al. Microhematuria: AUA/SUFU guideline, J Urol 2020; 204:778) (by either flexible or rigid cystoscopy/TURBT), including hematuria subjects referred due to suspicious/positive imaging, in order to determine the presence of urothelial carcinoma.
* Able to provide a voided urine sample of the required minimum volume
* Able to give written consent
* Able and willing to comply with study requirements
* Aged 18 years or older

Exclusion Criteria

* Prior history of bladder malignancy or pelvic radiotherapy. Prior history prostate or renal cell carcinoma within the last 5 years.
* Prior genitourinary manipulation (flexible or rigid cystoscopy / catheterisation, urethral dilation) in the 14 days before urine collection,
* Known current pregnancy
Jardiance® Post Marketing Surveillance (PMS) in Korean Patients With Chronic Heart Failure

The primary objective of this study is to monitor the safety profile of Jardiance® in Korean patient with chronic heart failure (New York Heart Association (NYHA) class II-IV) in a routine clinical setting.


Eligibility Criteria:
Inclusion criteria:

* Patients who have started at first time on Jardiance® in accordance with the approved label in Korea for heart failure (HF)
* Chronic heart failure (New York Heart Association (NYHA) class II-IV)
* Age ≥ 19 years at enrolment
* Patients who have signed on the data release consent form

Exclusion criteria:

* Patients with previous exposure to Jardiance®
* Known allergy or hypersensitivity to active ingredients empagliflozin or to any of the excipients
* Patients with type 1 diabetes or with prior history of diabetic ketoacidosis (DKA)
* Patient with renal impairment with estimated Glomerular Filtration Rate (eGFR) \< 20 mL/min/1.73 m²
* Patients with rare hereditary conditions of galactose intolerance, the Lapp lactase deficiency or glucose-galactose malabsorption
* Patient who are pregnant or are nursing or who plan to become pregnant while in the trial
* Patients for whom empagliflozin is contraindicated according local label of Jardiance®